Concerning this news, Citi Investment Research analyst Yaron Werber commented that the study results were strong, particularly in newly diagnosed patients. However he said the regimen is complicated because it includes five different types of pills and Abbot's ritonavir can cause serious side effects when taken with some other medications. Werber said he believes a regimen being studied by Gilead Sciences could produce similar cure rates with fewer pills. Gilead's approach uses two experimental pills, including its drug candidate sofosbuvir, as well as ribavirin. On Aug. 27, GILD announced the U.S. Food and Drug Administration had approved Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), a complete once-daily single tablet regimen for HIV-1 infection for treatment-naive adults. Stribild, referred to as "Quad" prior to FDA approval, combines four compounds in one daily tablet: elvitegravir, an integrase inhibitor, cobicistat, a pharmacoenhancing agent, emtricitabine and tenofovir disoproxil fumarate. Investors can anticipate that shares of GILD will continue to perform well if their experimental compounds produce similar cure rates to the one that ABT announced Monday. Their treatment focuses on both hepatitis B and C has the potential to powerfully increase their bottom line profits and earnings in the months to come. Make smarter trading decisions and provide investment ideas that could help make you richer. Bryan Ashenberg does the dirty work so you don't have to! Now let's look at another name from antiquity of yet another promising biopharmaceutical company. Isis was the name of a goddess in Ancient Egypt's religious system whose worship spread throughout the Greco-Roman world. Isis was worshipped as the ideal mother and wife as well as the patron of nature and magic. Her name literally meant "throne" as in the throne of the pharaoh. Her headdress was also a throne. As the personification of the throne, she was an important representation of the pharaoh's power. The pharaoh was said to have been her child who sat on a throne provided by his mother Isis. Quickly ascending to a pharmaceutical "throne" of great potential is what our next company, Isis Pharmaceutical ( ISIS)is in the process of accomplishing. ISIS engages in the discovery and development of antisense drugs using antisense drug discovery platform. Its product pipeline comprises 26 drugs to primarily treat cardiovascular, metabolic, severe, and rare diseases, as well as cancer.